People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...

The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...

Despite the highprice, the sales of Spravato increase 60% brought in $780 million in sales in the first nine months of 2024, compared to the same quarter in 2023. Spravato is a standalone ...

In the first nine months of 2024, Spravato recorded sales worth $780 million, up 61.5% year over year, driven by the ongoing launch and increased physician and patient demand. In the past 60 days ...

As per the third quarter earnings of Johnson & Johnson, Spravato brought in sales worth $780 million (roughly Rs. 6,747 crore) during the first nine months of 2024. In December, the company told ...

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

As Mattingly said, Spravato “turns on neural networks in a way that’s different.” He added, “Our standard oral antidepressants took weeks to months to see if they’re going to work.